Weak Statutory Earnings May Not Tell The Whole Story For Shandong Weigao Orthopaedic Device (SHSE:688161)
Weak Statutory Earnings May Not Tell The Whole Story For Shandong Weigao Orthopaedic Device (SHSE:688161)
Despite Shandong Weigao Orthopaedic Device Co., Ltd's (SHSE:688161) recent earnings report having lackluster headline numbers, the market responded positively. While shareholders may be willing to overlook soft profit numbers, we believe that they should also be taking into account some other factors which may be cause for concern.
儘管山東微致骨科醫療器械有限公司(SHSE:688161)最近的收益報告頭條數字不盡如人意,但市場的反應卻是積極的。 雖然股東們可能願意忽略利潤數字偏弱,但我們認爲他們也應該考慮到一些其他可能引起關注的因素。
How Do Unusual Items Influence Profit?
非常規項目如何影響利潤?
For anyone who wants to understand Shandong Weigao Orthopaedic Device's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥29m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Shandong Weigao Orthopaedic Device had a rather significant contribution from unusual items relative to its profit to September 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
對於想要了解山東微致骨科醫療器械公司超出法定數字的利潤的人,重要的是要注意,在過去十二個月中,法定利潤增長了約2900萬人民幣的飛凡項目。 雖然我們樂見利潤增長,但當飛凡項目做出重大貢獻時,我們往往會更加謹慎。 在分析了全球絕大多數上市公司後,我們發現重大的飛凡項目往往不會重複。 而且,畢竟,這正是會計術語所暗示的。 2024年9月,山東微致骨科醫療器械公司由於飛凡項目相對於其利潤的顯着貢獻,使其法定利潤相比於以往更強。 因此,我們可以推斷出這些飛凡項目使其法定利潤顯著強於否則可能的情況。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On Shandong Weigao Orthopaedic Device's Profit Performance
我們對山東微致骨科醫療器械公司的利潤表現的看法
As we discussed above, we think the significant positive unusual item makes Shandong Weigao Orthopaedic Device's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Shandong Weigao Orthopaedic Device's underlying earnings power is lower than its statutory profit. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. At Simply Wall St, we have analyst estimates which you can view by clicking here.
正如我們上面所討論的,我們認爲重要的正常外來因素使得山東威高骨科器械的收益成爲其潛在盈利能力的不佳指導。因此,我們認爲山東威高骨科器械的潛在盈利能力很可能低於其法定利潤。在進一步的壞消息中,其每股收益在過去一年中有所下降。歸根結底,要更全面地了解公司,不僅需要考慮以上因素。顯然,我們樂於考慮歷史數據來幫助我們對一家公司的看法。但考慮其他分析師的預測可能非常有價值。 在Simply Wall St,我們有分析師的預估數據,您可以通過點擊這裏查看。
This note has only looked at a single factor that sheds light on the nature of Shandong Weigao Orthopaedic Device's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
本注只討論了一個可以揭示山東威高骨科器械利潤性質的單一因素。但還有很多其他方式可以幫助您了解一家公司。例如,許多人將高股本回報視爲有利可圖的商業經濟指標,而其他人則喜歡「跟着錢走」,尋找內部人員正在買入的股票。因此,您可能希望查看這份免費的公司收藏,其中包括具有高股本回報率的公司,或者這份擁有高內部所有權的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。